sch 23982 has been researched along with butaclamol in 2 studies
| Studies (sch 23982) | Trials (sch 23982) | Recent Studies (post-2010) (sch 23982) | Studies (butaclamol) | Trials (butaclamol) | Recent Studies (post-2010) (butaclamol) |
|---|---|---|---|---|---|
| 87 | 0 | 0 | 233 | 3 | 2 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adams, EF; Fahlbusch, R; Nomikos, P; Reif, M; Schrell, UM | 1 |
| Caron, MG; Charpentier, S; Jarvie, KR; Severynse, DM; Tiberi, M | 1 |
2 other study(ies) available for sch 23982 and butaclamol
| Article | Year |
|---|---|
Growth of cultured human cerebral meningiomas is inhibited by dopaminergic agents. Presence of high affinity dopamine-D1 receptors.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Apomorphine; Benzazepines; Binding, Competitive; Bromocriptine; Butaclamol; Cell Division; Dopamine; Dopamine Agents; Humans; Meningioma; Receptors, Dopamine; Receptors, Dopamine D1; Tumor Cells, Cultured | 1990 |
Silencing of the constitutive activity of the dopamine D1B receptor. Reciprocal mutations between D1 receptor subtypes delineate residues underlying activation properties.
Topics: Adenylyl Cyclases; Arginine; Benzazepines; Binding, Competitive; Butaclamol; Cyclic AMP; Dopamine; Dose-Response Relationship, Drug; Humans; Isoleucine; Models, Molecular; Phenylalanine; Protein Conformation; Receptors, Dopamine D1; Receptors, Dopamine D5; Structure-Activity Relationship | 1996 |